A Glimpse Inside the Future of ATMP Supply Chains: Alison Pritchard on the Beyond Biotech Podcast
In an industry where innovation moves fast but patient access often lags behind, how can we build supply chains that are not only compliant and efficient, but also flexible and ready to scale?
That’s the question Alison Pritchard, Vice President of Business Development for Cryoport Systems, tackles in her recent interview with Beyond Biotech, the podcast from Labiotech.eu. In Episode 157, Alison sat down with host Dylan Kissane to explore the state of the advanced therapy medicinal products (ATMP) market in 2025 and what it will take to meet the rising expectations of therapeutic developers, regulators, and – most importantly – patients.
With firsthand insight into the challenges facing biopharma companies operating across Europe, the UK, and the Middle East, Alison shares how Cryoport Systems is enabling more strategic and patient-centric supply chain strategies. She discusses:
- The evolving ATMP landscape in EMEA, including persistent fragmentation and the opportunity for unified regulatory reform
- What’s driving the shift from logistics vendor to strategic supply chain partner
- Why early collaboration and data transparency are key to reducing risk in temperature-sensitive therapies
- How Cryoport Systems is preparing for what’s next, from expanding global infrastructure to collaboration with regulatory and clinical stakeholders.
“Even the most meticulously planned supply chain can be vulnerable to disruption,” Alison notes. “It’s not about eliminating every risk, it’s about building the systems and the teams to respond when the unexpected happens.”
Listen to the full episode to learn how Cryoport Systems is helping biopharma partners deliver on the promise of advanced therapies, and what lies ahead for the industry in the second half of 2025.
Listen now: Beyond Biotech Podcast Episode 157 – Cryoport Systems
